PXL770: dosing from clinical trials
Human schedule
PXL770 is an oral direct AMPK activator; in studies it was taken as capsules/tablets. Below is a generalization of the Phase 2a (STAMP-NAFLD) regimens.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Lower regimen | 250 mg once daily, oral | Starting dose |
| Split regimen | 250 mg twice daily (500 mg/day) | Increase if needed |
| Main studied regimen | 500 mg once daily | Maximum in this schedule |